topotecan has been researched along with Hematologic Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, G; Li, J; Miao, Y; Sun, Z; Tang, B | 1 |
| Beran, M; Cortes-Franco, JE; Estey, E; Giles, F; Kantarjian, HM; O'Brien, S; Thomas, DA; Tran, HT | 1 |
| Beran, M; Kantarjian, HM | 1 |
1 review(s) available for topotecan and Hematologic Neoplasms
| Article | Year |
|---|---|
Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Topotecan | 2000 |
1 trial(s) available for topotecan and Hematologic Neoplasms
| Article | Year |
|---|---|
Phase I study of oral topotecan in hematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Leukocyte Count; Male; Metabolic Clearance Rate; Middle Aged; Neutrophils; Platelet Count; Topotecan | 2003 |
1 other study(ies) available for topotecan and Hematologic Neoplasms
| Article | Year |
|---|---|
Targeting of STAT5 using the small molecule topotecan hydrochloride suppresses acute myeloid leukemia progression.
Topics: Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Recurrence; STAT5 Transcription Factor; Topotecan | 2023 |